Table 1.
Demographic and clinical characteristics of EOC patients included in this study.
| Overall (N = 454) | Training group (N = 317) | Validation group (N = 137) | P value | |
|---|---|---|---|---|
| Age (years) | ||||
| ≤70 | 378 (83.3%) | 268 (84.5%) | 110 (80.3%) | 0.329 |
| ≥71 | 76 (16.7%) | 49 (15.5%) | 27 (19.7%) | |
| Race | ||||
| White | 393 (86.6%) | 276 (87.1%) | 117 (85.4%) | 0.86 |
| Black | 14 (3.1%) | 9 (2.8%) | 5 (3.6%) | |
| Others | 47 (10.4%) | 32 (10.1%) | 15 (10.9%) | |
| Marital status | ||||
| Married | 272 (59.9%) | 186 (58.7%) | 86 (62.8%) | 0.162 |
| Single | 81 (17.8%) | 53 (16.7%) | 28 (20.4%) | |
| Others | 101 (22.2%) | 78 (24.6%) | 23 (16.8%) | |
| Histologic type | ||||
| Clear cell | 20 (4.4%) | 13 (4.1%) | 7 (5.1%) | 0.819 |
| Endometrioid | 21 (4.6%) | 14 (4.4%) | 7 (5.1%) | |
| Mucinous | 7 (1.5%) | 4 (1.3%) | 3 (2.2%) | |
| Serous | 406 (89.4%) | 286 (90.2%) | 120 (87.6%) | |
| Grade | ||||
| I | 10 (2.2%) | 9 (2.8%) | 1 (0.7%) | 0.658 |
| II | 71 (15.6%) | 51 (16.1%) | 20 (14.6%) | |
| III | 335(73.8%) | 232 (73.2%) | 103 (75.2%) | |
| Unknown | 38 (8.4%) | 25 (7.9%) | 13 (9.5%) | |
| Laterality | ||||
| Bilateral | 275 (60.6%) | 191 (60.3%) | 84 (61.3%) | 0.554 |
| Unilateral | 156 (34.4%) | 112 (35.3%) | 44 (32.1%) | |
| Unknown | 23 (5.1%) | 14 (4.4%) | 9 (6.6%) | |
| FIGO stage | ||||
| I/II | 28 (6.2%) | 20 (6.3%) | 8 (5.8%) | 1 |
| III/IV | 426 (93.8%) | 297 (93.7%) | 129 (94.2%) | |
| T stage | ||||
| T1 | 12 (2.6%) | 10 (3.2%) | 2 (1.5%) | 0.785 |
| T2 | 26 (5.7%) | 18 (5.7%) | 8 (5.8%) | |
| T3 | 118 (26.0%) | 82 (25.9%) | 36 (26.3%) | |
| T4 | 298 (65.6%) | 207 (65.3%) | 91 (66.4%) | |
| N stage | ||||
| N0 | 137 (30.2%) | 98 (30.9%) | 39 (28.5%) | 0.682 |
| N1 | 317 (69.8%) | 219 (69.1%) | 98 (71.5%) | |
| M stage | ||||
| M0 | 272 (59.9%) | 194 (61.2%) | 78 (56.9%) | 0.455 |
| M1 | 182 (40.1%) | 123 (38.8%) | 59 (43.1%) | |
| Surgical approach | ||||
| PE | 40 (8.8%) | 34 (10.7%) | 6 (4.4%) | 0.188 |
| APE | 13 (2.9%) | 7 (2.2%) | 6 (4.4%) | |
| PPE | 357 (78.6%) | 246 (77.6%) | 111 (81.0%) | |
| TPE | 38 (8.4%) | 26 (8.2%) | 12 (8.8%) | |
| EPE | 6 (1.3%) | 4 (1.3%) | 2 (1.5%) | |
| Radiotherapy | ||||
| No/unknown | 449 (98.9%) | 314 (99.1%) | 135 (98.5%) | 1 |
| Yes | 5 (1.1%) | 3 (0.9%) | 2 (1.5%) | |
| Chemotherapy | ||||
| No/unknown | 80 (17.6%) | 58 (18.3%) | 22 (16.1%) | 0.66 |
| Yes | 374 (82.4%) | 259 (81.7%) | 115 (83.9%) | |
| CA125 | ||||
| Positive | 370 (81.5%) | 260 (82.0%) | 110 (80.3%) | 0.484 |
| Negative | 16 (3.5%) | 9 (2.8%) | 7 (5.1%) | |
| Unknown | 68 (15.0%) | 48 (15.1%) | 20 (14.6%) | |
| Lymph nodes examined | ||||
| 1∼12 | 154 (33.9%) | 108 (34.1%) | 46 (33.6%) | 0.953 |
| 13∼25 | 139 (30.6%) | 98 (30.9%) | 41 (29.9%) | |
| ≥26 | 161 (35.5%) | 111 (35.0%) | 50 (36.5%) | |
| Lymph nodes positive | ||||
| 0∼8 | 356 (78.4%) | 254 (80.1%) | 102 (74.5%) | 0.221 |
| ≥9 | 98 (21.6%) | 63 (19.9%) | 35 (25.5%) | |
| LNR | ||||
| (0, ≤0.03) | 150 (33.0%) | 109 (34.4%) | 41 (29.9%) | 0.651 |
| (>0.03, ≤0.32) | 146 (32.2%) | 100 (31.5%) | 46 (33.6%) | |
| (>0.32, 1.00) | 158 (34.8%) | 108 (34.1%) | 50 (36.5%) | |
| LODDS | ||||
| (−2.25, ≤−1.18) | 124 (27.3%) | 91 (28.7%) | 33 (24.1%) | 0.551 |
| (>−1.18, ≤−0.25) | 183 (40.3%) | 127 (40.1%) | 56 (40.9%) | |
| (>−0.25, 2.26) | 147 (32.4%) | 99 (31.2%) | 48 (35.0%) | |
| Tumor size (mm) | ||||
| <38 | 62 (13.7%) | 46 (14.5%) | 16 (11.7%) | 0.245 |
| ≥38 | 288 (63.4%) | 205 (64.7%) | 83 (60.6%) | |
| Unknown | 104 (22.9%) | 66 (20.8%) | 38 (27.7%) | |